These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. The Development of Inhibitors Targeting the Mixed Lineage Leukemia 1 (MLL1)-WD Repeat Domain 5 Protein (WDR5) Protein- Protein Interaction. Ye X; Chen G; Jin J; Zhang B; Wang Y; Cai Z; Ye F Curr Med Chem; 2020; 27(33):5530-5542. PubMed ID: 31132972 [TBL] [Abstract][Full Text] [Related]
12. Structural basis of nucleosome recognition and modification by MLL methyltransferases. Xue H; Yao T; Cao M; Zhu G; Li Y; Yuan G; Chen Y; Lei M; Huang J Nature; 2019 Sep; 573(7774):445-449. PubMed ID: 31485071 [TBL] [Abstract][Full Text] [Related]
13. Regulation of MLL1 H3K4 methyltransferase activity by its core components. Dou Y; Milne TA; Ruthenburg AJ; Lee S; Lee JW; Verdine GL; Allis CD; Roeder RG Nat Struct Mol Biol; 2006 Aug; 13(8):713-9. PubMed ID: 16878130 [TBL] [Abstract][Full Text] [Related]
14. Analysis of the binding of mixed lineage leukemia 1 (MLL1) and histone 3 peptides to WD repeat domain 5 (WDR5) for the design of inhibitors of the MLL1-WDR5 interaction. Karatas H; Townsend EC; Bernard D; Dou Y; Wang S J Med Chem; 2010 Jul; 53(14):5179-85. PubMed ID: 20575550 [TBL] [Abstract][Full Text] [Related]
15. High-affinity, small-molecule peptidomimetic inhibitors of MLL1/WDR5 protein-protein interaction. Karatas H; Townsend EC; Cao F; Chen Y; Bernard D; Liu L; Lei M; Dou Y; Wang S J Am Chem Soc; 2013 Jan; 135(2):669-82. PubMed ID: 23210835 [TBL] [Abstract][Full Text] [Related]
16. Discovery of Chen W; Chen X; Li D; Zhou J; Jiang Z; You Q; Guo X J Med Chem; 2021 Jun; 64(12):8221-8245. PubMed ID: 34105966 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of the H3K4 methyltransferase MLL1/WDR5 complex attenuates renal senescence in ischemia reperfusion mice by reduction of p16 Shimoda H; Doi S; Nakashima A; Sasaki K; Doi T; Masaki T Kidney Int; 2019 Nov; 96(5):1162-1175. PubMed ID: 31570196 [TBL] [Abstract][Full Text] [Related]
18. Hematopoietic transformation in the absence of MLL1/KMT2A: distinctions in target gene reactivation. Chen Y; Ernst P Cell Cycle; 2019 Jul; 18(14):1525-1531. PubMed ID: 31161857 [TBL] [Abstract][Full Text] [Related]
19. Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with in vivo antitumor activity. Chen W; Chen X; Li D; Wang X; Long G; Jiang Z; You Q; Guo X Eur J Med Chem; 2021 Nov; 223():113677. PubMed ID: 34225179 [TBL] [Abstract][Full Text] [Related]
20. Targeting human SET1/MLL family of proteins. Vedadi M; Blazer L; Eram MS; Barsyte-Lovejoy D; Arrowsmith CH; Hajian T Protein Sci; 2017 Apr; 26(4):662-676. PubMed ID: 28160335 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]